logo image

Sargramostim information from DrugsUpdate  

See Available Brands of Sargramostim in India

Sargramostim is indicated after induction chemotherapy in AML patients and transplantation of autologous peripheral blood progenitor cells. Sargramostim is also prescribed for myeloid reconstitution after autologous and allogeneic BMT. The drug is also indicated for patients who have BMT failure or engraftment delay.


No information available


No information available

Sargramostim Indications / Sargramostim Uses

No information available

Sargramostim Adverse Reactions / Sargramostim Side Effects

Some of the commonly reported adverse events of Sargramostim are lower back pain, fatigue, chills, myalgia, mild bone pain, facial flushing, dizziness, diarrhoea, headache, weakness, fainting, flu-like symptoms, dyspnoea, rapid weight gain, edema in the extremities and sudden weight gain.


The drug is contraindicated in patients with fluid retention, respiratory and CVD.

Special Precautions

No information available

Other Drug Interactions

Sargramostim may interact with prednisone, AZT, lithium, vitamins, dexamethasone, and certain vitamins.

Other Interactions

No information available


Dosage of Sargramostim should be as prescribed by a physician


No information available

List of Contraindications

Sargramostim and Pregnancy

USFDA pregnancy category C. May be or may not be harmful to an unborn baby. Consult your doctor if you are in gestation or planning to have a baby during Sargramostim treatment.

Sargramostim and Lactation

It is not known whether Sargramostim can pass through the breast milk or not. Nursing mothers should avoid breastfeeding while taking Sargramostim.

Sargramostim and Children

Sargramostim should not be used in children unless prescribed by a pediatrician

Sargramostim and Geriatic

No information available

Sargramostim and Other Contraindications

No information available


No information available

Lab interference

No information available

Sargramostim brands in India:


© 2011-2018 DrugsUpdate.com. Disclaimer | Site Map